AB Corporate Bond ETF (NASDAQ:EYEG) Stock Price Crosses Below 200-Day Moving Average – Time to Sell?

Shares of AB Corporate Bond ETF (NASDAQ:EYEG) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $35.48 and traded as low as $34.76. AB Corporate Bond ETF shares last traded at $34.7690, with a volume of 18 shares traded.

AB Corporate Bond ETF Trading Up 0.3%

The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.07 and a current ratio of 3.07. The stock has a market capitalization of $27.96 million, a P/E ratio of -20.80 and a beta of 0.17. The stock has a 50-day moving average price of $35.15 and a two-hundred day moving average price of $35.47.

AB Corporate Bond ETF Cuts Dividend

The business also recently declared a monthly dividend, which was paid on Tuesday, July 7th. Investors of record on Wednesday, July 1st were issued a $0.1358 dividend. The ex-dividend date was Wednesday, July 1st. This represents a c) annualized dividend and a yield of 4.7%. AB Corporate Bond ETF’s payout ratio is -102.98%.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in EYEG. Jane Street Group LLC bought a new position in AB Corporate Bond ETF in the 2nd quarter worth $232,000. Wealth Enhancement Advisory Services LLC boosted its stake in shares of AB Corporate Bond ETF by 32.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 157,702 shares of the specialty pharmaceutical company’s stock valued at $5,634,000 after purchasing an additional 38,685 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in shares of AB Corporate Bond ETF during the fourth quarter valued at about $34,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

AB Corporate Bond ETF Company Profile

EyeGate Pharmaceuticals, Inc is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.